Established in Jerusalem in 1901, today they are the world's largest producer of generic pharmaceuticals. Acquired Actavis Generics from Allergan in 2016 for US$40.5 billion.
|Teva Pharmaceutical Industries Ltd||ISR||website|
|Teva Pharmaceutical Industries Ltd|
In 2021, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of B.
Source: CDP (2021)
In 2021, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of B.
Source: CDP (2021)
This company received a score of 34.2/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
Source: Newsweek (2017)
In 2016 this company agreed to pay more than $519 million to settle US criminal and civil allegations that the company bribed officials in Mexico, Russia and Ukraine to gain business for its medications.
Source: news article (2016)
In 2019 several pharmaceutical companies finally settled a 2005 lawsuit which claimed the companies fudged wholesale drug prices to increase Medicaid reimbursements. In all, the state of Illinois received a combined $648 million over the course of that litigation. This company paid US$135 million to wrap up the allegations in 2019.
Source: news article (2019)
This company received an S&P Global ESG Score of 36/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 7 Feb 2021). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2021)
A 2015 report by Sum Of Us reveals that the largest pharmaceutical corporations are complicit in fuelling one of the most serious public health crises facing society today. Pharmaceutical companies, including this one, are sourcing active pharmaceutical ingredients (APIs) from companies in China which are responsible for massive environmental pollution from its antibiotic factories. Teva has links with at least three of the Chinese companies identified in the report, all of which have been in the Chinese media spotlight for various offences including improper waste management and the release of noxious chemicals.
Source: Changing Markets (2015)
In 2015 this company agreed to pay US$1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. The settlement stems from charges brought in 2008 against Cephalon Inc, which was acquired by Teva in 2012.
Source: news article (2015)
This company has products that are certified by the Carbon Trust, signifying that the carbon footprint of selected products has been measured, managed and reduced. A life cycle product carbon footprint is determined by calculating the total greenhouse gas emissions generated by a product, from extraction of raw-materials, to end-of-life.
Source: Carbon Trust (2021)
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target.
Source: We Mean Business (2021)
This company has Responsibility claims on its website.
Source: company website (2018)
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)
|Revenue||22 billion USD (2017)|
|Subsidiaries||Teva Pharma Australia Pty Ltd|
|Address||Petah Tikva, Israel|